{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "M",
          "alt": "I",
          "position": "26"
        },
        "variant_string_id": "DJ-1 M26I"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The paper defines Parkinson disease as associated with loss of DJ-1 protein due to genomic deletions or mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we demonstrate that the M26I mutation reduces DJ-1 expression, particularly in a null background.",
          "judgment": "Yes",
          "reasoning": "The paper shows that M26I mutation affects DJ-1 expression and is relevant to Parkinson disease."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls included for this assay were both Normal/Negative/Wild type AND Abnormal/Positive/Null.",
          "judgment": "Yes",
          "reasoning": "The paper mentions using basic controls for the assay."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays (continued)",
          "extracted_paper_info": "The variant M26I was used as a control.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that the variant M26I was used as a control."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation was performed.",
          "judgment": "Yes",
          "reasoning": "The paper does not perform an OddsPath calculation for the M26I mutation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation (continued)",
          "extracted_paper_info": "At least 11 total benign/pathogenic controls were used across the entire study.",
          "judgment": "Yes",
          "reasoning": "The paper uses multiple controls for the assay."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "This variant leads to loss of DJ-1 protein expression, contributing to Parkinson disease. The functional evidence is supporting pathogenic due to the impact on DJ-1's cytoprotective activity."
    },
    {
      "variant_id": {
        "Gene": "DJ-1",
        "Protein_Change": {
          "ref": "C",
          "alt": "A",
          "position": "106"
        },
        "variant_string_id": "DJ-1 C106A"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkinson disease (PD)-associated genomic deletions and the destabilizing L166P point mutation lead to loss of the cytoprotective DJ-1 protein.",
          "judgment": "Yes",
          "reasoning": "The paper defines Parkinson disease as associated with loss of DJ-1 protein due to genomic deletions or mutations."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Here we demonstrate that the M26I mutation reduces DJ-1 expression, particularly in a null background.",
          "judgment": "Yes",
          "reasoning": "The paper shows that M26I mutation affects DJ-1 expression and is relevant to Parkinson disease."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Basic controls included for this assay were both Normal/Negative/Wild type AND Abnormal/Positive/Null.",
          "judgment": "Yes",
          "reasoning": "The paper mentions using basic controls for the assay."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays (continued)",
          "extracted_paper_info": "The variant C106A was used as a control.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states that the variant C106A was used as a control."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "No OddsPath calculation was performed.",
          "judgment": "Yes",
          "reasoning": "The paper does not perform an OddsPath calculation for the C106A mutation."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation (continued)",
          "extracted_paper_info": "At least 11 total benign/pathogenic controls were used across the entire study.",
          "judgment": "Yes",
          "reasoning": "The paper uses multiple controls for the assay."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "This variant affects DJ-1's cytoprotective activity, contributing to Parkinson disease. The functional evidence is supporting pathogenic."
    }
  ]
}